Oric Pharmaceuticals agrees with Cancer Research UK to fund early clinical development of Oric-259

Oric Pharmaceuticals said Cancer Research UK will fully fund and execute early clinical development of Oric-259, and Oric retains an option to reacquire Oric-259 rights after Phase 1/2 data.